Chao Wu

Dr. Chao Wu


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2018 in BMC Medical Genomics
Verified
Journal Article
Open access
PDF file
LWLingyan Wang
Lingyan Wang
XYXiaoling Yu
Xiaoling Yu
CWChao Wu
Chao Wu
TZTeng Zhu
Teng Zhu
WWWenming Wang
Wenming Wang
HJHongzhong Jin
Hongzhong Jin
Generalized pustular psoriasis (GPP) is a rare, episodic, potentially life-threatening inflammatory disease. However, the pathogenesis of GPP, and universally accepted therapies for treating it, remain undefined. To better understand the disease mechanism of GPP, we performed a transcriptome analysis to profile the gene expression of peripheral blood mononuclear cells (PBMCs) from patients enrolled at the time of diagnosis and receiving follow-up treatment for up to 6 months. RNA sequencing data revealed that gene expression in five GPP patients’ PBMCs was profoundly altered following acitretin treatment. Differentially expressed gene (DEG) analysis suggested that genes related to psoriatic inflammation, including CXCL1, CXCL8 (IL-8), S100A8, S100A9, S100A12 and LCN2, were significantly downregulated in patients in remission from GPP. Functional enrichment and annotation analysis unveiled a cluster of DEGs significantly associated with the function of leukocytes, particularly neutrophils. Pathway analysis suggested that a variety of pro-inflammatory pathways were inhibited in patients in remission. This analysis not only reaffirmed known signaling pathways in GPP pathogenesis, but also implicated novel factors and pathways, such as cell cycle regulation pathways. Furthermore, regulator network analysis provided bioinformatics-based support for upstream molecules as potential therapeutic targets such as oncostatin M. This longitudinal analysis of blood transcriptomes provides the first evidence that dysregulated gene expression in peripheral blood may significantly contribute to psoriatic inflammation in GPP patients. Novel canonical pathways and biomarkers identified in the current research may provide insights to help understand GPP pathobiology and advance novel therapeutics.

16 August 2023 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
BSBiao Song
Biao Song
CWChao Wu
Chao Wu
WLWeida Liu
Weida Liu
YWYa-Nan Wang
Ya-Nan Wang
XNXin Ning
Xin Ning
HJHongzhong Jin
Hongzhong Jin
In-depth analysis of circulating proteome alterations identified that erythrodermic psoriasis (EP) presented a dysregulated serum proteome with distinct inflammation elevation, immune activation and metabolic disturbance. We found that EP harboured a blended immune milieu with distinct T helper (Th)17/Th1 skewing and mild Th2 activation. Additionally, atherosclerosis signalling were substantially increased in EP.

1 August 2019 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
CWChao Wu
Chao Wu

29 September 2026 in Journal of Cutaneous Medicine and Surgery
Verified
Journal Article
Closed access
SWSifan Wang
Sifan Wang
CWChao Wu
Chao Wu

1 January 2026 in Dermatologic Therapy
Verified
Journal Article
Open access
PDF file
CWChao Wu
Chao Wu
DLDian-Mo Li
Dian-Mo Li
XZXin-Yuan Zhang
Xin-Yuan Zhang
DSDan Shu
Dan Shu
WWWen-Ming Wang
Wen-Ming Wang
HJHongzhong Jin
Hongzhong Jin
Background: Hyperuricemia (HUA) is common in psoriasis, but the effect of selective interleukin (IL)‐23 inhibition on serum uric acid (UA) is inconsistent. Methods: In this two‐center retrospective cohort, 228 adults with chronic plaque psoriasis received guselkumab for 52 weeks. The primary outcome was the change in UA (ΔUA). Secondary outcomes included HUA resolution, new‐onset HUA, predictors of baseline HUA and HUA resolution, and the association of ΔUA with Psoriasis Area and Severity Index (PASI) response and change in high‐sensitivity C‐reactive protein (ΔhsCRP). Results: At baseline, 92 patients (40.4%) had HUA. UA decreased in the overall cohort (median ΔUA −10.5 μmol/L; bootstrap 95% CI −19.0 to −3.0; p < 0.001), with the largest reduction among baseline HUA patients (median −35.5 μmol/L; 95% CI −53.5 to −17.0), 32.6% of whom achieved HUA resolution; cohort HUA prevalence fell from 40.4% to 33.3% (McNemar p = 0.023). 10.3% of patients with normal baseline UA developed new‐onset HUA. ΔUA correlated weakly with ΔhsCRP but not with PASI change. Male sex and higher BMI independently predicted baseline HUA; lower baseline total cholesterol and higher baseline PASI independently predicted HUA resolution. Conclusion: Guselkumab was associated with a statistically significant but modest UA reduction, which was largest in patients with HUA and was independent of skin clearance over 52 weeks, suggesting an ancillary metabolic effect of IL‐23 inhibition that warrants prospective confirmation.

1 May 2026 in Clinical, Cosmetic and Investigational Dermatology
Verified
Journal Article
Open access
CWChao Wu
Chao Wu
YWYong-Jun Wang
Yong-Jun Wang
TLTie-Jun Liu
Tie-Jun Liu
HJHongzhong Jin
Hongzhong Jin
Hidradenitis suppurativa (HS) is a chronic, recurrent inflammatory skin disorder. Laboratory parameters may serve as an assessment tool, providing a potential objective window into disease activity. To systematically evaluate the utility of commonly obtained laboratory parameters in the objective assessment of disease severity in patients with HS. This single-center retrospective study included patients who were clinically diagnosed with HS, acne inversa, or follicular occlusion triad at Peking Union Medical College Hospital between January 1, 2020, and July 1, 2025. Study data were extracted from clinical examination records and corresponding laboratory test results. Ordinal logistic regression models were constructed to evaluate the associations between laboratory parameters and Hurley stages. Heterogeneity analyses were performed to assess the consistency of these associations across anatomical regions. The study included 1750 clinical visits from 583 HS patients, with a male predominance (85.7%) and a mean age of 31.15±12.11 years. By systematically comparing laboratory parameters across Hurley stages, this study identified significant differences in ten markers, including white blood cell (WBC), neutrophil ratio (NEU%), platelet (PLT), plateletcrit (PCT), mean platelet volume (MPV), hemoglobin (Hb), gamma-glutamyl transferase (GGT), high-density lipoprotein cholesterol (HDL-C), erythrocyte sedimentation rate (ESR), and high-sensitivity C-reactive protein (hsCRP). Ordinal logistic regression analyses demonstrated that WBC, NEU%, PLT, PCT, platelet distribution width (PDW), GGT, ESR, and hsCRP were significantly and positively associated with increasing Hurley stage, while Hb, MPV, and HDL-C exhibited inverse associations. Heterogeneity analysis found that systemic inflammation-related markers (WBC, PDW, ESR, and hsCRP) demonstrated highly consistent associations with HS severity across anatomical locations, while metabolic parameters (HDL-C, triglycerides (TG), alanine aminotransferase (ALT), and aspartate aminotransferase (AST)) exhibited significant site-specific heterogeneity. This study supports the use of readily available laboratory markers as an objective adjunct to conventional clinical severity assessments, while highlighting the anatomical specificity of HS pathophysiology.